Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clathrin interactor 1 (CLINT1) is a protein containing an ENTH domain involved in clathrin-mediated trafficking at the trans-Golgi network and endosomes, functioning as an adaptor protein for the formation and maturation of clathrin-coated vesicles[1][4][3]. CLINT1 interacts with clathrin, AP-1 adaptor protein, SNARE proteins, phosphoinositides, and other trafficking proteins, promoting vesicle assembly and cargo selection, and is structurally related to the epsin protein family[1][2][3][4]. CLINT1 plays a key role in intracellular trafficking and homeostasis; its dysfunction is implicated in susceptibility to schizophrenia and other psychiatric conditions in humans[1][3][4], is regulated by miR-145 in bladder cancer[1], and is essential for epidermal development in animal models, with loss leading to inflammation and skin barrier defects resembling psoriasis[2]. No direct pharmacological modifiers or clinical biomarkers are presently reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clathrin interactor 1 (CLINT1).